LONDON, Nov. 7, 2016 /PRNewswire/ -- The adult vaccines market has been forecasted to increase at a compound annual growth rate (CAGR) of around 6% over the next five years. Adults are as likely as children to die from diseases that they can be immunized. For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Adult vaccines continue to be one of the growing segment for pharmaceutical companies. The driving factors for adult vaccines growth are an increasing acceptance of adult vaccines and the public health focus on flu prevention, as well as introductions of new vaccines. The vaccines industry also faces hindrances such as vaccine safety, shortages and delays, vaccine development time line as well as entry barriers for new manufacturers. Adult Vaccines Market - Disease Wise AnalysisThe influenza vaccines capture maximum share of the total adult vaccines market. It is the most popular and accepted vaccination amongst adults. The hepatitis vaccines account for second highest share of the total adult vaccines market in 2015. The HPV/cervical cancer vaccines and pneumococcal vaccines captures the third and fourth highest share of the adult vaccines market respectively in 2015. While vaccines for zoster shingles and DTP are also gaining ground in adult vaccines market landscape. Adult Vaccines Market - Company AnalysisNote: Novartis divested its non-influenza vaccine business to GlaxoSmithKline (GSK) and CSL acquired Novartis influenza vaccines business. In 2010, GSK was the leader in the adult vaccines market but it lost the leadership position to Merck. Sanofi Pasteur stands at the second position in the adult vaccines market landscape. GSK slipped to third position in the global adult vaccines market in 2014. While Pfizer stands at the fourth spot in the adult vaccines market landscape. Adult Vaccines Market - Disease Wise Company Sales AnalysisGSK generates maximum adult vaccines sales from Hepatitis and DTP vaccines, while Sanofi Pasteur remains focused on maintaining its leadership in the influenza vaccines market. The cervical cancer and zoster shingles vaccines contributes maximum share of the total Merck adult vaccines sales. Novartis main source of adult vaccines sales revenue is the influenza vaccines.In 2011, Sanofi Pasteur replaced GSK and became the dominant player in the influenza vaccines landscape, while in the cervical cancer vaccines market, Merck is at the forefront and is expected to maintain its dominancy over a longer period of time. GSK is the clear leader in hepatitis vaccines market.